Transition Therapeutics completes enrollment in Phase II diabetes trial

The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a six-month follow-up.

Approximately 80 patients with type 2 diabetes have been enrolled in the study. Patients receive a daily treatment of TT-223 in addition to their current regimen of oral glucose lowering agents (metformin and/or thiazolidinediones).

Transition and Eli Lilly and Company have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize gastrin-based therapies, including the lead compound TT-223. Gastrin-based therapies are an emerging class of potential disease-modifying therapies for patients with diabetes, and have been shown to provide sustained improvement in glycemic control in preclinical models and early clinical studies.

Transition is a biopharmaceutical company, which develops novel therapeutics for disease indications with large markets. Transition’s lead products include ELND005 for the treatment of Alzheimer’s disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.